EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

T-Cell Redirecting Therapies in Multiple Myeloma: Pathogenesis and Management of Toxicities Beyond CRS and ICANS

Katia Mancuso iD, Marco Talarico, Enrica Manzato, Simona Barbato iD, Paola Tacchetti iD, Elena Zamagni iD, Michele Cavo iD

Cancers · 30.04.2025 · 17 (9) · 1514

DOI: 10.3390/cancers17091514 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 30.04.2025. Verfasst von Katia Mancuso und 6 weiteren Autor:innen. Beteiligte Einrichtung: IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", 40138 Bologna, Italy. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 141 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The introduction of chimeric antigen receptor T (CAR-T) cell and bispecific antibody (BsAb) therapies has revolutionized multiple myeloma (MM) treatment, offering exceptional efficacy, and culminating in recent regulatory approval. However, these therapies have brought unique toxicity challenges, manifesting not only with the well-established cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), but also with the emergence of other common and equally distinctive toxicities, including cytopenias, hypogammaglobulinemia, infections, and the rare but life-threatening immune effector cell-like lymphohistiocytosis syndrome (IEC-HS). These adverse events are characterized by unique mechanisms of action that differ from those of previous treatments for MM, thereby requiring specialized knowledge to optimize day-to-day management and ultimately maximize therapeutic benefits while ensuring patient safety. Additionally, the toxicity profiles of these T-cell engager therapies are becoming increasingly important in treatment decisions, with implications for patient selection and therapy sequencing. In this review, we provide a comprehensive overview of the current state-of-the-art regarding the incidence, etiopathogenetic mechanisms, and clinical manifestations of these increasingly less non-prototypical but still lesser-known side effects than CRS and ICANS, in order to offer clear and actionable insights into their effective management, while emphasizing critical points for future improvement, in view of the increasing number of MM patients who will benefit from the newly approved and upcoming immunotherapies.

Schlagwörter

Stichwörter der Autor:innen

T-cell redirecting therapiescytopeniashematologic toxicitieshypogammaglobinemiaimmune effector cell associated hematotoxicityimmune effector cell-like lymphohistiocytosis syndromeimmunotherapyinfectionsmultiple myeloma

Autor:innen und Institutionen

  • IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", 40138 Bologna, Italy.
  • Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, 40138 Bologna, Italy.

ORCID-Profile: Katia Mancuso, Simona Barbato, Paola Tacchetti, Elena Zamagni, Michele Cavo

Zitieren

APA

Mancuso, K., Talarico, M., Manzato, E., Barbato, S., Tacchetti, P., Zamagni, E., & Cavo, M. (2025). T-Cell Redirecting Therapies in Multiple Myeloma: Pathogenesis and Management of Toxicities Beyond CRS and ICANS. Cancers, 17(9), 1514. https://doi.org/10.3390/cancers17091514

Vancouver

Mancuso K, Talarico M, Manzato E, Barbato S, Tacchetti P, Zamagni E, et al. T-Cell Redirecting Therapies in Multiple Myeloma: Pathogenesis and Management of Toxicities Beyond CRS and ICANS. Cancers. 2025;17(9):1514. doi:10.3390/cancers17091514

BibTeX
@article{Mancuso2025,
  author = {Mancuso, Katia and Talarico, Marco and Manzato, Enrica and Barbato, Simona and Tacchetti, Paola and Zamagni, Elena and Cavo, Michele},
  title = {T-Cell Redirecting Therapies in Multiple Myeloma: Pathogenesis and Management of Toxicities Beyond CRS and ICANS},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {9},
  pages = {1514},
  doi = {10.3390/cancers17091514}
}
Kostenlos starten →